Astec LifeSciences Limited — Important, 27-01-2025: General Updates

Astec LifeSciences Limited's Board has convened a meeting, approving the unaudited financial results for the quarter and nine-months ended December 31, 2024. The results indicate a significant decline, with a standalone loss of ₹4,040.01 lakh, down from ₹2,434.55 lakh in the previous year. Revenue from operations stood at ₹9,385.84 lakh, highlighting a robust increase from ₹5,079.45 lakh year-on-year, but expenses exceeded income, leading to a negative profit margin of -43.04%.

In a strategic move for sustainability, the Board approved an equity investment of up to ₹3.75 crore in a proposed Special Purpose Vehicle with Clean Max Enviro Energy for solar power generation, reflecting a commitment to long-term renewable energy consumption. Additionally, Mr. R. R. Govindan has been reappointed as a Non-Executive & Independent Director for a second term.

The Company is set to conduct a postal ballot for the reappointment and is optimistic about potential growth in renewable energy initiatives, positioning itself as a player in the green energy segment amidst current operational challenges.